vida: research session 2026-05-04 — 9 sources archived

Pentagon-Agent: Vida <HEADLESS>

inbox/queue/2025-11-xx-mdpi-nutrients-glp1-appetite-eating-disorders-psychosocial.md

@@ -0,0 +1,54 @@
+---
+type: source
+title: "Beyond Weight Loss: GLP-1 Usage and Appetite Regulation in the Context of Eating Disorders and Psychosocial Processes"
+author: "MDPI Nutrients (multiple authors)"
+url: https://pmc.ncbi.nlm.nih.gov/articles/PMC12694361/
+date: 2025-11-01
+domain: health
+secondary_domains: []
+format: paper
+status: unprocessed
+priority: high
+tags: [glp1, eating-disorders, appetite, psychosocial, behavioral-health, anorexia, binge-eating]
+intake_tier: research-task
+---
+
+## Content
+
+Review paper examining GLP-1 receptor agonists' effects on appetite regulation and eating disorder risk across different eating disorder subtypes. Published in MDPI Nutrients, archived on PMC (PMC12694361).
+
+Key findings:
+- GLP-1 RAs reduce hunger, increase satiety, dampen cravings, and influence food choice by activating brain regions controlling fullness and modulating reward circuits
+- Users typically experience smaller meals, longer eating intervals, and reduced emotional eating short-term — but these benefits may not persist long-term
+- Opposing mechanism paradox: beneficial for BED (reduces binge episodes via mesolimbic dopamine), potentially harmful for restrictive EDs (enhanced satiety reinforces restriction in vulnerable individuals)
+- Highest-risk populations: individuals with restrictive eating disorder histories (AN, atypical AN), those with high perfectionism or OCD traits, adolescents during critical development, racial/ethnic minorities facing intersectional stigma
+
+Clinical recommendations:
+1. Pre-treatment screening: SCOFF questionnaire for eating disorder history, compensatory behaviors, body image, and emotion regulation
+2. Ongoing monitoring: track eating behaviors, mood, and suicidal ideation; heightened vigilance during dose escalations
+3. Multidisciplinary approach: psychological care + dietitian + medical oversight (not standalone medication)
+4. Preventive strategies: introduce DBT/mindfulness BEFORE appetite suppression eliminates food-based coping
+5. Conclusion: GLP-1s "must be approached with caution: integrated into multidisciplinary care with rigorous monitoring" until long-term safety in diverse populations established
+
+Research gaps: "extremely limited" evidence on anorexia nervosa specifically; theoretical risks include appetite suppression masking restrictive behaviors, compulsive reliance on medication for control, reinforcement of maladaptive food rules
+
+## Agent Notes
+**Why this matters:** This is the most comprehensive review connecting GLP-1 pharmacology specifically to eating disorder risk by subtype — it operationalizes the paradox that the same mechanism (GLP-1R-mediated appetite suppression) is protective for BED and potentially harmful for AN. This is the mechanistic frame needed to interpret the VigiBase aROR 4.17-6.80 signal.
+
+**What surprised me:** The finding that benefits (smaller meals, reduced emotional eating) "may not persist long-term" — even for BED — suggests GLP-1 is not a durable behavioral treatment for any eating disorder subtype. This is consistent with the continuous-treatment dependency pattern established in earlier sessions for metabolic indications.
+
+**What I expected but didn't find:** Specific RCT evidence for GLP-1 in anorexia nervosa (AN) — the paper confirms this is essentially absent. The AN evidence base is entirely theoretical/mechanistic.
+
+**KB connections:**
+- [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] — eating disorder risk constrains behavioral health expansion
+- [[human-in-the-loop clinical AI degrades to worse-than-AI-alone]] — parallel to GLP-1 creating unintended behavioral consequences
+- [[behavioral primacy — health outcomes 80-90% determined by non-clinical factors]] — this paper argues behavioral risk factors (ED history, perfectionism) are the primary determinant of whether GLP-1 helps or harms
+
+**Extraction hints:** Multiple claim candidates: (1) GLP-1 eating disorder risk is subtype-specific — protective for BED, potentially harmful for restrictive EDs; (2) no RCT evidence for GLP-1 in AN exists despite pharmacovigilance signals; (3) pre-treatment ED screening is recommended but not required by any professional guideline or regulatory body
+
+**Context:** This is a broad narrative review, not an RCT or systematic review. Useful for the mechanistic argument but not primary evidence.
+
+## Curator Notes (structured handoff for extractor)
+PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
+WHY ARCHIVED: Mechanistic framework for interpreting the pharmacovigilance eating disorder signal — explains WHY the signal exists via subtype-specific GLP-1R mechanism
+EXTRACTION HINT: Focus on the BED-protective vs. AN-harmful mechanism distinction; extractor should NOT collapse eating disorders into a single category